Abstract
Multidrug-resistant (MDR) tuberculosis, defined as tuberculosis resistant to the two first-line drugs isoniazid and rifampin, poses a serious problem for global tuberculosis control strategies. Lack of a safe and convenient model organism hampers progress in combating the spread of MDR strains of Mycobacterium tuberculosis We reasoned that auxotrophic MDR mutants of M. tuberculosis would provide a safe means for studying MDR M. tuberculosis without the need for a biosafety level 3 (BSL3) laboratory. Two different sets of triple auxotrophic mutants of M. tuberculosis were generated, which were auxotrophic for the nutrients leucine, pantothenate, and arginine or for leucine, pantothenate, and methionine. These triple auxotrophic strains retained their acid-fastness, their ability to generate both a drug persistence phenotype and drug-resistant mutants, and their susceptibility to plaque-forming mycobacterial phages. MDR triple auxotrophic mutants were obtained in a two-step fashion, selecting first for solely isoniazid-resistant or rifampin-resistant mutants. Interestingly, selection for isoniazid-resistant mutants of the methionine auxotroph generated isolates with single point mutations in katG, which encodes an isoniazid-activ...Continue Reading
References
Aug 13, 1992·Nature·Y ZhangS Cole
Mar 1, 1995·Infection and Immunity·R A McAdamW R Jacobs
Apr 1, 1994·Antimicrobial Agents and Chemotherapy·L P MillerT M Shinnick
May 25, 1999·Infection and Immunity·M JacksonC Guilhot
May 29, 1999·Science·M A BehrP M Small
Apr 18, 2000·Infection and Immunity·M K HondalusB R Bloom
Mar 21, 2002·The Lancet Infectious Diseases·Marcel A Behr
May 16, 2002·Infection and Immunity·Bhavna G GordhanValerie Mizrahi
Oct 9, 2002·Microbiology·Stoyan BardarovWilliam R Jacobs
Jul 25, 2006·Vaccine·Vasan K SambandamurthyWilliam R Jacobs
Jun 30, 2009·PloS One·Chirajyoti DebPappachan E Kolattukudy
Mar 10, 2010·Antimicrobial Agents and Chemotherapy·Hiroki AndoTeruo Kirikae
Jun 19, 2010·PloS One·Gavin J RyanAnne J Lenaerts
Jan 27, 2012·Journal of Clinical Microbiology·Paras JainWilliam R Jacobs
Oct 23, 2012·Virology·Deborah Jacobs-SeraGraham F Hatfull
Oct 27, 2011·Applied Biosafety : Journal of the American Biological Safety Association·Bing ChenWilliam R Jacobs
Aug 27, 2013·PloS One·Wen ZhangKanglin Wan
Mar 22, 2014·PLoS Pathogens·Graham F Hatfull
Jun 5, 2014·MBio·Paras JainWilliam R Jacobs
May 1, 2015·Journal of Clinical Microbiology·Max R O'DonnellMichelle H Larsen
Jun 25, 2015·Microbiology Spectrum·Catherine Vilchèze, William R Jacobs
Jul 30, 2015·Proceedings of the National Academy of Sciences of the United States of America·Michael BerneyWilliam R Jacobs
Sep 15, 2015·Expert Review of Vaccines·Tony W NgSteven A Porcelli
Sep 28, 2016·Journal of Bacteriology·Oren MayerWilliam R Jacobs
Nov 1, 2016·MBio·Paras JainWilliam R Jacobs
Mar 25, 2017·Microbiology Spectrum·Catherine Vilchèze, Laurent Kremer
Citations
Jul 8, 2020·Antimicrobial Agents and Chemotherapy·Catherine VilchèzeWilliam R Jacobs
Jan 27, 2019·Nature Reviews. Immunology·David G RussellBrian C VanderVen
Sep 5, 2019·Frontiers in Microbiology·Jomien M MoutonSamantha L Sampson
May 3, 2019·Science Translational Medicine·Steven A Porcelli, William R Jacobs
Dec 12, 2020·Frontiers in Microbiology·Hiroyuki YamadaSatoshi Mitarai
Jan 17, 2021·International Journal of Molecular Sciences·Anna Allué-GuardiaJordi B Torrelles
Sep 10, 2020·Journal of Bacteriology·Paras JainKyle J Minch
Jan 21, 2021·MBio·Catherine VilchèzeWilliam R Jacobs
Jul 28, 2019·Microbiology Spectrum·Gabriel T MashabelaDigby F Warner
Jul 31, 2019·Accounts of Chemical Research·Timothy J de WetValerie Mizrahi
Jul 20, 2021·Antimicrobial Agents and Chemotherapy·Loes van SchieNico Callewaert
Dec 2, 2021·The Journal of Antimicrobial Chemotherapy·Chen-Yi CheungGregory M Cook